Lack of association between +405 G/C polymorphism in VEGF and breast cancer risk: A meta-analysis

J BUON. Jul-Aug 2015;20(4):970-7.

Abstract

Purpose: To explore whether the vascular endothelial growth factor (VEGF) +405 G/C polymorphism confers susceptibility to breast cancer (BC) by conducting a meta-analysis.

Methods: Publications addressing the association between the VEGF +405 G/C polymorphism and BC risk were selected from the PubMed, Embase and Google Scholar databases. Data were extracted from studies by three independent reviewers. The meta-analysis was performed by STATA 12.0 software, and odds ratio (OR) with 95% confidence interval (CI) were calculated.

Results: Finally, 10 case-control studies were retrieved with a total of 8,855 BC patients and 9,393 controls. No significant association was identified between VEGF +405 G/C polymorphism and BC risk in overall populations under 5 models (C vs G: OR=1.001, 95% CI=0.896-1.119, p=0.987; CC vs GG: OR=1.006, 95% CI=0.853-1.186, p=0.997; CG vs GG: OR= 0.985, 95% CI=0.823-1.178, p=0.779; CC vs CGs/GG: OR=1.019, 95% CI=0.921-1.127, p=0.722; CC/CG vs GG: OR=0.985, 95% CI=0.835-1.162, p=0.862), and also in the subgroup analysis by ethnicity.

Conclusion: Our study confirms that there is a lack of association between the VEGF +405 G/C polymorphism and BC risk.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / etiology
  • Breast Neoplasms / genetics*
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Polymorphism, Single Nucleotide*
  • Publication Bias
  • Risk
  • Vascular Endothelial Growth Factor A / genetics*

Substances

  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A